Skip to content

Clinical Comprehensive Evaluation of Drugs for the Treatment of Methicillin-Resistant Staphylococci

Clinical Comprehensive Evaluation of Drugs for the Treatment of Methicillin-Resistant Staphylococci

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125045
Enrollment
Unknown
Registered
2026-05-20
Start date
2025-01-02
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection

Interventions

Vancomycin/Norvancomycin group:None
Daptomycin group:None

Sponsors

Shandong Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients with confirmed or suspected Gram-positive bacterial infection (such as staphylococcus, streptococcus, Enterococcus, corynebacterium, etc.) can include various types of infection, such as bloodstream infection, infective endocarditis, respiratory system infection, abdominal infection, skin and soft tissue infection, bone and joint infection, central nervous system infection, and urinary tract infection. 2. Use of study drugs: (norepinephrine) vancomycin or teicoplanin or linezolid or daptomycin; 3. No age limit; 4. Gender is not limited; 5. No race limit.

Exclusion criteria

Exclusion criteria: 1. Use of the initial target drug for less than three days; 2. Insufficient data before and after treatment were available for efficacy evaluation.; 3. The patient had used the target drug in another hospital at the time of this infection. 4. Non-standard route of administration, such as vancomycin for irrigation; 5. Other drugs of this study were combined at the same time. 6. Patients or their families refused to sign informed consent to participate in the study. 7. Use of other study drugs was preceded by use of the target drug.

Design outcomes

Primary

MeasureTime frame
The clinical effective rate at the end of treatment of the study drug;

Secondary

MeasureTime frame
Efficacy evaluation on the 3rd/4th day;Safety endpoint evaluation;All-cause mortality rate within 28 days;Healing verification test;

Countries

China

Contacts

Public ContactZhang Yahui

Shandong Provincial Hospital

zhangyy1982@126.com+86 531 6877 6461

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026